Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency

Recruiting now · Phase 4

Conditions studied: Alpha 1-Antitrypsin, COPD, Antibody Deficiency

In brief

The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.

Key facts

Study ID

NCT07135427

Run by

University of Alabama at Birmingham

People needed

30

Starts

2025-09-03

Expected to finish

2027-06-01

Last updated by the study team

2025-11-10

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults who are heterozygous for a SERPINA1 Z allele
• Have either had no COPD exacerbations or 2 or more exacerbations in the previous year
• Has not received a pneumococcal conjugate vaccine within the past 5 years, or has only received the pneumococcal polysaccharide vaccine in the past

You may not qualify if…

• Received a pneumococcal conjugate vaccine within the past 5 years
• Known allergy, severe adverse reaction, or other sensitivity to pneumococcal conjugate vaccines

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.